Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966383 | 0.79 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL23267820 | 0.78 | HTR6 (0.40) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL17489068 | 0.78 | HTR6 (0.40) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6969158 | 0.75 | HTR6 (0.35) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL7628328 | 0.74 | HTR6 (0.33) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL28077993 | 0.73 | OPRL1 (0.50) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL15508612 | 0.72 | HTR6 (0.41) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6976334 | 0.72 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25829140 | 0.72 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL7490294 | 0.72 | HTR6 (0.36) | HTR6HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1106615-B1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HTR6 418/4885HPGD 608/4885KMT2A 2262/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | HTR6 368/4885HPGD 439/4885KMT2A 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.